Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Phase 3

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: Fluoruracil
Drug: Leucovorin
Drug: Capecitabine
Drug: Oxaliplatin
Radiation: Radiation

First Posted Date: 2024-01-16

Last Posted Date: 2024-12-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 250

Registration Number: NCT06205485

Locations: 🇺🇸
Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States
🇺🇸
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 50 locations

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Phase 3

Recruiting

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: ASKB589
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Placebo
Drug: Tislelizumab

First Posted Date: 2024-01-16

Last Posted Date: 2024-03-25

Lead Sponsor: AskGene Pharma, Inc.

Target Recruit Count: 780

Registration Number: NCT06206733

Locations: 🇨🇳
Beijing cancer hospital, Beijing, China

Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Radiation: node-sparing short-course radiotherapy
Drug: Sintilimab
Drug: Capecitabine
Drug: Oxaliplatin
Procedure: TME surgery
Procedure: watch and wait

First Posted Date: 2024-01-12

Last Posted Date: 2024-01-12

Lead Sponsor: Jinhua Central Hospital

Target Recruit Count: 37

Registration Number: NCT06204094

Locations: 🇨🇳
Zhejiang University Affiliated Jinhua Hospital, Jinhua, Zhejiang, China

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Liposomal irinotecan
Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-18

Lead Sponsor: Harbin Medical University

Target Recruit Count: 63

Registration Number: NCT06192680

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Phase 3

Recruiting

Conditions: Locally Advanced Unresectable or Metastatic Gastric Cancer
Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions: Drug: M108 monoclonal antibody
Drug: Placebo
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2023-12-20

Last Posted Date: 2024-02-28

Lead Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd

Target Recruit Count: 486

Registration Number: NCT06177041

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

Recruiting

Conditions: Fruquintinib
Irinotecan
Capecitabine
Gastrointestinal Tumours

Interventions: Device: fruquintinib
Drug: Irinotecan
Drug: Capecitabine

First Posted Date: 2023-12-13

Last Posted Date: 2023-12-13

Lead Sponsor: China Medical University, China

Target Recruit Count: 50

Registration Number: NCT06169202

Locations: 🇨🇳
First Hospital of China Medical University, Shenyang, Liaoning, China

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Not Applicable

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Mitoxantrone hydrochloride liposome
Drug: Capecitabine

First Posted Date: 2023-12-05

Last Posted Date: 2023-12-05

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 24

Registration Number: NCT06156761

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 2

Recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Capecitabine
Drug: Disitamab Vedotin
Drug: Toripalimab
Drug: oxaliplatin

First Posted Date: 2023-12-04

Last Posted Date: 2023-12-14

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 90

Registration Number: NCT06155383

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳
Shandong Cancer Hospital & Institute, Jinan, Shangdong, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

and more 8 locations